Shares of Canadian biotech Aeterna Zentaris plummeted nearly 56% on 6 November after the FDA rejected the company's new drug application (NDA) for Macrilen (macimorelin acetate), an ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD).
Shares of Canadian biotech Aeterna Zentaris plummeted nearly 56% on 6 November after the FDA rejected the company's new drug application (NDA) for Macrilen (macimorelin acetate), an ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD).
The Quebec City, Quebec firm's stock closed at 65 cents on 6 November,
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
